drugset / Trial / NCT02079207

Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine

NCT02079207

Phase 3 Completed 767 enrolled SK Chemicals Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study will assess the Immunogenicity and safety of 13-valent Pneumococcal Conjugate Vaccine compared with 23-valent Pneumococcal Polysaccharide Vaccine. All participants should be naïve of Pneumococcal vaccine.

Timeline

Start
2013-12
Primary completion
2014-10
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject NBP606 Unknown 0.5 ml
Comparator ProDiax-23 Vaccine 0.5 ml